James Bicher MD, Founder and Director of Bicher Cancer Institute

Answer/Response to Stephen Barrett MD

Stephen Barrett, MD is an unlicensed psychologist who dedicates his life to criticize, defamate (from defamation), and "try" very hard to ruin Alternative and Complementary doctors and practitioners reputation in the internet, with no much success.

He is the creator and also maintain the disgraceful famous websites, casewatch.org, and quackwatch.org. We all know that people are famous for two things: when you are good and help your fellow human beings, or when you are so sick, twisted, and have such bad intentions AGAINST your fellow human beings. I do not need to tell you where you will include Stephen Barrett.

Dr James I. Bicher have been investigated by the Medical Board of California regarding a complaint that a relative of one of his patients filed it.

As you might know, any patient can go to a medical board of any state and file a complain for any thing she/he believes is not right regarding the treatment received at her/his doctor.

The medical board "HAS THE OBLIGATION TO ACT UPON ANY COMPLAIN" and determine if the it is correct or not. On the process, the medical board will issue an "Accusation". The accusation is in place and public until the situation is resolved.

In Dr James Bicher MD case, the board found some medical bookkeeping deficiencies, and put Dr Bicher on 5 years probation. After three years of probation, Dr Bicher appealed the medical board decision and the probation was lifted, on November 19, 2009.

After the decision of the medical board to terminate Dr Bicher's probation, Stephen Barrett continues to maliciously post the old medical board accusation and early decision, but he does not clearly states that Dr Bicher's medical situation with the medical board has been clear.

You can make your own conclusion by browsing "Stephen Barrett MD" and also reading any of his websites, and find out for your self if there is any value on what Stephen Barrett is doing to make his living. I will suggest him to start doing something that help ANYBODY and make a decent living working honestly.

If you have any question, you can reach me at 310-398-0013, or email me at carlosdc@vci.org.

Thanks for reading this post.

Carlos D Caridad
Vice President Internet Marketing
Valley Cancer Institute
Bicher Cancer Institute

Hyperthermia, FDA approved Alternative Cancer Treatment

Today, in his facility in Culver City, Los Angeles area, California, Dr. James Bicher's institute provides 6 Hyperthermia treatment rooms, and a fully equipped Radiation Department, including an IMRT device. Hyperthermia and IMRT are a very successful combination to treat many kind of tumors, spearing normal tissues. IMRT is a Radiation technique, that focuses radiation therapy to target only the tumor, avoiding surrounded areas as much as possible (definitely much more than conventional radiation). The Valley Cancer Institute clinic has the capacity of treating about 50 patients a day, making it the largest Hyperthermia facility in the US and on of the largest of the world.

Dr. James Bicher MD protocol has been very successful treating breast cancer, prostate cancer, head and neck cancer, and other tumors locations.

Bicher Cancer Institute, formerly known as Valley Cancer Institute, has been operating in Culver City, California for about 19 years, since November 1989.

Dr James Bicher is opening a second clinic named Bicher Cancer Institute in Beverly Hills, in middle 2010.

Dr James I. Bicher in front of his new Clinic in 455 N. Roxbury Dr, Beverly Hills 90210, to be open soon

Some publications you could find in the Internet about James Haim Bicher, M.D.:

XXVIII International Clinical Hyperthermia Society,

Mumbai, India.

The Meeting took place on January 6th and 7th, 2007.

H

    Dr. James Bicher presented two papers at the ICHS Meeting:

 1. The Role of Local Blood Flow, Rheological Properties and Free Radicals in Hyperthermia-Induced in Cerebral Tissue Damage

    2. A Method of Curative Thermoradiotherapy in Superficial Tumors; Breast, Head and Neck, and Prostate

The Role of Local Blood Flow, Rheological Properties and Free Radicals in Hyperthermia-Induced in Cerebral Tissue Damage

James I. Bicher, Nodar P. Mitagvaria*, Marina I. Nebieridze*

Valley Cancer Institute, Los Angeles, California, USA

*Beritashvili Institute of Physiology, Georgian Academy of Sciences,

Tbilisi, Georgia

 Objective. We tried the sensitivity of cerebral tissue to hyperthermia as manifested by histological changes and the role of local blood flow, blood rheological properties, and free radicals in development of mentioned changes.

.Research design and methods. Local areas of cerebral surface were irrigated by artificial cerebrospinal fluid heated up to the temperature necessary for achievement of stable level of temperature (41, 43 or 45⁰C). Serial brain coronal sections 50 mm thick stained with Azure-Eosin were analyzed under light microscope. The local cerebral blood flow was measured by thermal clearance method. Blood rheological properties were changed by injection of high molecular weight Dextran T-500 and free radicals existence was controlled by Dimethyl sulfoxide injection.

Results. At 41⁰C just superficial lesions of the cerebral cortex and a few cases of thrombosed cerebral microvessels have been observed. The rise of temperature on 2⁰C resulted in very severe lesions of cerebral tissue; the layered structure of the cerebral cortex in the central parts of the hyperthermia–induced lesions was impaired. The highest temperature (45⁰C) caused complete destruction of the layered structure of the cortex in the area of hyperthermic exposure, numerous areas with lost neurons and thrombosed cerebral vessels with perivascular accumulation of erythrocytes were revealed. Injection of Dextran T-500 resulted in deterioration and injection of Dimethyl sulfoxide in significant improvement of histological changes in cerebral tissue when 43 or 45⁰C hyperthermia is used. Bi-phase alterations of local cerebral blood flow have been revealed at 43⁰C hyperthermia. Pronounced hyperemia in first stage of heating is followed by remarkable ischemia on the late stage.

Conclusion. High sensitivity of cerebral tissue to hyperthermic exposure has been confirmed. We can consider cerebrovascular thrombosis as one of the most significant complication of brain hyperthermia. In case of deteriorated blood rheological properties hyperthermia-induced cerebral lesion is more remarkable. Administration of antioxidants, scavengers of free radicals can partially lessen hyperthermia induced cerebral lesion.

A Method of Curative Thermoradiotherapy in Superficial Tumors; Breast, Head and Neck, and Prostate

James I. Bicher, M.D., and Ralph S. Wolfstein, M.D.

Valley Cancer Institute, Los Angeles, California U.S.A.

 Objective: To evaluate the effectiveness of hyperfractionated thermoradiotherapy (HTRT) in patients suffering from early stage cancers of the breast, head and neck and prostate that refuse conventional radiation surgery or chemotherapy.  Response rates and survival were determined using objective end points.  (MRI, MRS, PET scan and tumor markers).

Material and Methods: Fractionation used involved daily hyperthermia treatments in conjunction with each radiation fraction.  Radiation daily doses are progressively decreased from 180 to 100 cGy resulting in protracted treatment time that decreases the isoeffect biological equivalent dose by 15% to 25%.  This decrease is compensated by the increased number of hyperthermia fractions which potentiates each radiation dose. Treatment is continued until an objective complete response is attained, or failure determined.  40 breast patients, 27 head and neck and 18 prostate patients were treated with a follow up of two to five years.  All patients were early stage (less than III).

Results:  Complete response rates were 82% for breast patients, 88% for head and neck and 93% for prostate patients.  Projected 5 year survival rates were 80% for breast patients, 88% for head and neck, and 87% for prostate patients.  Side effects were less than with curative radiation therapy alone.  No Grade IV toxicity (Common Toxicity Criteria) was observed. 

Conclusion: Protracted hyperfractionation of daily thermoradiotherapy decreases the side effects of radiation therapy, allows treating to effect using objective end point parameters, accomplishes a high percentage of complete responses and a high 5-year survival rate in the 80-90% range in early superficial tumors.  It can be considered as potentially curative in Stage I-II breast, head and neck and prostate cancer when used and researched as such.